Pulmonary hypertension natural history: Difference between revisions

Jump to navigation Jump to search
No edit summary
Kristin Feeney (talk | contribs)
No edit summary
Line 1: Line 1:
{{Pulmonary hypertension}}
{{CMG}}
{{CMG}}



Revision as of 12:17, 8 September 2011

Pulmonary Hypertension Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulmonary hypertension from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pulmonary hypertension natural history On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Pulmonary hypertension natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary hypertension natural history

CDC on Pulmonary hypertension natural history

Pulmonary hypertension natural history in the news

Blogs on Pulmonary hypertension natural history

Directions to Hospitals Treating Pulmonary hypertension

Risk calculators and risk factors for Pulmonary hypertension natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Survival:

The National Institutes of Health (NIH)Registry estimated a median survival of 2.8 years for symptomatic patients with idiopathic pulmonary hypertension who do not recieve any treatment.

1, 3,and 5-year survival rates for untreated patients with idiopathic pulmonary hypertension were 68%, 48%, and 34%, respectively. Studies from Japan,India and Mexico have suggested similar results.

The median survival duration was even lower for patients with pulmonary hypertension that was associated with another disease like portal hypertension, and Scleroderma(2-year survival of 40% if untreated).

Prognosis

The long-term prognosis has been poor, but new treatments may lead to better results. Some people with this condition may have heart failure that could lead to death. Assessment of prognosis in patients with pulmonary arterial hypertension (PAH) is important since it influences both medical therapy and referral for transplantation.

Surprisingly, patients with Eisenmenger syndrome have a more favorable hemodynamic profile and prognosis than adults with idiopathic or primary pulmonary hypertension.[1]

Indicators of Poor Prognosis:

  • Age>45 at presentation.
  • Poor exercise capacity.
  • Elevated Brain Natriuretic Peptide.
  • Pericardial effusion.
  • Elevated RA size and pressure.
  • RV significant dysfunction or failure.
  • Low cardiac index.
  • Decreased pulmonary arterial capacitance.
  • Underlying Scleroderma or Liver disease.
  1. Hopkins WE,Ochoa LL, Richardson GW, Trulock EP(1996) Comparison of the hemodynamics and survival or patients with severe pulmonary hypertension or Eisenmenger Syndrome.